173 related articles for article (PubMed ID: 36370634)
21. Peripheral CD19
Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
[TBL] [Abstract][Full Text] [Related]
22. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
Aktas O; Smith MA; Rees WA; Bennett JL; She D; Katz E; Cree BAC;
Ann Neurol; 2021 May; 89(5):895-910. PubMed ID: 33724534
[TBL] [Abstract][Full Text] [Related]
23. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
[TBL] [Abstract][Full Text] [Related]
24. Case report: Transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder.
Osborne B; Romanow G; Hemphill JM; Zarif M; DeAngelis T; Kaplan T; Oh U; Pinkhasov J; Patterson K; Levy M
Front Neurol; 2024; 15():1352779. PubMed ID: 38689876
[TBL] [Abstract][Full Text] [Related]
25. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
26. Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis.
Yan L; Kimko H; Wang B; Cimbora D; Katz E; Rees WA
Clin Pharmacokinet; 2022 Mar; 61(3):387-400. PubMed ID: 34718986
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
[TBL] [Abstract][Full Text] [Related]
28. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.
Pittock SJ; Zekeridou A; Weinshenker BG
Nat Rev Neurol; 2021 Dec; 17(12):759-773. PubMed ID: 34711906
[TBL] [Abstract][Full Text] [Related]
29. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
30. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
Duchow A; Paul F; Bellmann-Strobl J
Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
[TBL] [Abstract][Full Text] [Related]
31. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
Illés Z
Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
[TBL] [Abstract][Full Text] [Related]
32. Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report.
Lehrieder D; Zapantis N; Pham M; Schuhmann MK; Haarmann A
Front Neurol; 2023; 14():1297341. PubMed ID: 38073644
[TBL] [Abstract][Full Text] [Related]
33. Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model.
Lazzaro C; Mazzanti NA; Rossi S; Parazzini F
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1185-1200. PubMed ID: 37795872
[TBL] [Abstract][Full Text] [Related]
34. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder.
Mealy MA; Levy M
Medicine (Baltimore); 2019 Jun; 98(25):e15944. PubMed ID: 31232925
[TBL] [Abstract][Full Text] [Related]
35. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders.
Stathopoulos P; Dalakas MC
Expert Rev Clin Immunol; 2022 Sep; 18(9):933-945. PubMed ID: 35899480
[TBL] [Abstract][Full Text] [Related]
36. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
37. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.
Wilson R; Makuch M; Kienzler AK; Varley J; Taylor J; Woodhall M; Palace J; Leite MI; Waters P; Irani SR
Brain; 2018 Apr; 141(4):1063-1074. PubMed ID: 29447335
[TBL] [Abstract][Full Text] [Related]
38. Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Masuda H; Mori M; Hirano S; Uzawa A; Uchida T; Muto M; Ohtani R; Aoki R; Kuwabara S
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):32-40. PubMed ID: 34362853
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
Romeo AR
Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
